Hemostemix Inc. (HEM.V)
CAD 0.1
(26.67%)
CAD 0.1
(26.67%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | - CAD | 0.0% |
| 2022 | - CAD | 100.0% |
| 2021 | -342.70 CAD | 99.25% |
| 2020 | -45.51 Thousand CAD | -241.8% |
| 2019 | -13.31 Thousand CAD | 84.91% |
| 2018 | -88.24 Thousand CAD | -42.23% |
| 2017 | -62.04 Thousand CAD | 16.64% |
| 2016 | -74.42 Thousand CAD | 6.61% |
| 2015 | -79.69 Thousand CAD | 70.17% |
| 2014 | -267.14 Thousand CAD | -10.87% |
| 2013 | -240.95 Thousand CAD | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q2 | - CAD | 0.0% |
| 2024 Q1 | - CAD | 0.0% |
| 2023 FY | - CAD | 0.0% |
| 2023 Q2 | - CAD | -100.0% |
| 2023 Q1 | 1.00 CAD | 0.0% |
| 2023 Q4 | - CAD | 0.0% |
| 2023 Q3 | - CAD | 0.0% |
| 2022 Q1 | -14.46 Thousand CAD | 95.78% |
| 2022 FY | - CAD | 100.0% |
| 2022 Q2 | -10.56 Thousand CAD | 26.94% |
| 2022 Q3 | -6671.00 CAD | 36.87% |
| 2022 Q4 | - CAD | 100.0% |
| 2021 Q3 | -5370.00 CAD | 81.84% |
| 2021 Q1 | -41.87 Thousand CAD | 97.97% |
| 2021 Q2 | -29.57 Thousand CAD | 29.37% |
| 2021 FY | -342.70 CAD | 99.25% |
| 2021 Q4 | -342.7 Thousand CAD | -6281.75% |
| 2020 Q2 | -181.67 Thousand CAD | -354.22% |
| 2020 Q3 | -164.85 Thousand CAD | 9.26% |
| 2020 Q4 | -2.06 Million CAD | -1151.49% |
| 2020 Q1 | -39.99 Thousand CAD | 47.21% |
| 2020 FY | -45.51 Thousand CAD | -241.8% |
| 2019 Q4 | -75.76 Thousand CAD | -24.69% |
| 2019 FY | -13.31 Thousand CAD | 84.91% |
| 2019 Q3 | -60.76 Thousand CAD | -27.92% |
| 2019 Q2 | -47.5 Thousand CAD | 33.67% |
| 2019 Q1 | -71.61 Thousand CAD | 62.55% |
| 2018 FY | -88.24 Thousand CAD | -42.23% |
| 2018 Q4 | -191.21 Thousand CAD | -32.7% |
| 2018 Q3 | -144.09 Thousand CAD | -74.75% |
| 2018 Q2 | -82.45 Thousand CAD | -16.71% |
| 2018 Q1 | -70.65 Thousand CAD | 20.73% |
| 2017 Q1 | -14.18 Thousand CAD | 84.32% |
| 2017 Q2 | -31.85 Thousand CAD | -124.58% |
| 2017 Q3 | -255.2 Thousand CAD | -701.13% |
| 2017 Q4 | -89.12 Thousand CAD | 65.08% |
| 2017 FY | -62.04 Thousand CAD | 16.64% |
| 2016 Q4 | -90.43 Thousand CAD | -2.0% |
| 2016 FY | -74.42 Thousand CAD | 6.61% |
| 2016 Q1 | -81.21 Thousand CAD | 17.64% |
| 2016 Q2 | -31.82 Thousand CAD | 60.81% |
| 2016 Q3 | -88.66 Thousand CAD | -178.59% |
| 2015 Q1 | -276.66 Thousand CAD | -3.56% |
| 2015 Q4 | -98.6 Thousand CAD | 67.71% |
| 2015 Q3 | -305.41 Thousand CAD | -6.32% |
| 2015 Q2 | -287.26 Thousand CAD | -3.83% |
| 2015 FY | -79.69 Thousand CAD | 70.17% |
| 2014 Q2 | - CAD | 0.0% |
| 2014 Q1 | - CAD | 0.0% |
| 2014 FY | -267.14 Thousand CAD | -10.87% |
| 2014 Q4 | -267.14 Thousand CAD | 0.0% |
| 2014 Q3 | - CAD | 0.0% |
| 2013 FY | -240.95 Thousand CAD | 0.0% |
| 2013 Q2 | - CAD | 0.0% |
| 2013 Q3 | - CAD | 0.0% |
| 2013 Q4 | - CAD | 0.0% |
| 2013 Q1 | - CAD | 0.0% |
| 2012 Q4 | - CAD | 0.0% |
| 2012 Q3 | - CAD | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| Arch Biopartners Inc. | - CAD | NaN% |
| Covalon Technologies Ltd. | 5.94 Million CAD | 100.0% |
| Universal Ibogaine Inc. | - CAD | NaN% |
| Kane Biotech Inc. | 250.41 Thousand CAD | 100.0% |
| MedMira Inc. | 182.42 Thousand CAD | 100.0% |
| Marvel Biosciences Corp. | - CAD | NaN% |
| NervGen Pharma Corp. | - CAD | NaN% |
| XORTX Therapeutics Inc. | - CAD | NaN% |